Recent Bioscience Sector releases

Anti-GBM disease: A model for autoimmune kidney diseases

[PRESSWIRE] Weimar, Germany - 29 October, 2018 -- The renewed interest in anti-GBM disease is spurred by the detection of autoantibodies in other forms of glomerulonephritis and has led to an exciting development in studies on pathogenesis as well as diagnosis and management. The newly published review [1] by Professor Mårten Segelmark, gives a comprehensive update on Anti-GBM disease subgroups, pathogenesis and therapies. “A must-read for all nephrologist”, explains Professor Denis Fouque, editor-in-chief of Nephrology Dialysis and Transplantation (NDT), the journal in which the review was published.

Achieve Announces Results of Clinical Study Demonstrating Similar Bioavailability for a New Cytisine Formulation in Fed and Fasted Subjects

[PRESSWIRE] SEATTLE and VANCOUVER, British Columbia, Sept. 27, 2018 -- Achieve Life Sciences, Inc. (NASDAQ :ACHV ), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced results of a clinical study evaluating the effect of food on the bioavailability of a new formulation for cytisine.

Lithuania intends to take on the Reference Member State role from UK for 70 Mutual and Decentralised Procedures

[PRESSWIRE] London, United Kingdom - 06 August, 2018 -- The United Kingdom (UK) submitted on 29 March 2017 the notification of its intention to withdraw from the Union pursuant to Article 50 of the Treaty on European Union (EU). This means that the United Kingdom will become a 'third country' from 30 March 2019. According to Directive 2001/83/EC the reference member state (RMS) must be a member of the EU.

Healthcare Companies Capitalizing on a Resurgent Biotech Industry

 [PRESSWIRE] LAS VEGAS, March 20, 2018 -- The healthcare sector has always been one of the best performing industries in the stock market over the last several decades. In fact, since 1963 the healthcare sector has generated an annualized rate of return of 11 percent. Included in today's commentary: Endonovo Therapeutics, Inc. (OTC: ENDV), Athersys, Inc. (NASDAQ: ATHX), Caladrius Biosciences (NASDAQ: CLBS), ARCA Biopharma, Inc. (NASDAQ: ABIO), Geron Corporation (NASDAQ: GERN).

Micell Technologies Announces Expanded Patent Estate

 [PRESSWIRE] DURHAM, North Carolina, March 20, 2018 -- Micell® Technologies, Inc., a privately-held, development-stage biomedical company, today provided an update on its recently expanded intellectual property portfolio.

AGC Biologics Expands Capacity at Berkeley, California Facility

 [PRESSWIRE] BERKELEY, California, March 6, 2018 -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today that their Berkeley, California facility is adding to its growing capacity with the addition of a 2000L single-use bioreactor (SUB).

Partners Agree on Initial Funding to Kick Off Waste-to-chemistry Project in Rotterdam

 [PRESSWIRE] MONTREAL, February 16, 2018 -- A consortium of companies comprising Air Liquide, AkzoNobel Specialty Chemicals, Enerkem and the Port of Rotterdam has signed a project development agreement covering initial investments in an advanced waste-to-chemistry facility in Rotterdam.

Enterome Raises €32 Million ($38.5 Million) in a Series D Financing

 [PRESSWIRE] PARIS and CAMBRIDGE, Massachusetts, January 4, 2018 -- ENTEROME SA, a clinical-stage biotech company pioneering innovative therapies to treat microbiome-associated diseases with a focus on inflammatory bowel diseases (IBD) and immuno-oncology (IO) indications, announces that it has raised €32 million in a Series D financing.

JHL Biotech Welcomes New Chief Medical Officer, Rong Chen

 [PRESSWIRE] HSINCHU, Taiwan and WUHAN, China, Jan. 1, 2018 -- JHL Biotech announced that Rong Chen has been appointed Chief Medical Officer effective January 1. As CMO, Dr. Chen will oversee JHL's medical and clinical development work as part of its mission to make world-class biopharmaceuticals affordable and available to more patients.

Santa Claus and Rudolph the green-nosed reindeer are on a mission to fight global warming

[PRESSWIRE] ROLLE, SWITZERLAND and the Arctic Circle, Finland - 19 December, 2017 -- Santa’s famous and much beloved reindeer are part of the ruminant animal family and therefore produce harmful greenhouse gases. It is said that Santa’s nine reindeer in total travel more than 342 million kilometres around the world on their mission to deliver Christmas presents to eager children, and as a result produce roughly 15 tons of methane gas a year.